Teva

Type
Offshoring/Delocalisation
Country
Ireland
Region
Ireland; Eastern and Midland;
Location of affected unit(s)
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
New offshoring locations
Bulgaria
110 jobs
Number of planned job losses
Job loss
Announcement Date
7 May 2021
Employment effect (start)
1 October 2022
Foreseen end date
1 January 2023

Description

Pharmaceutical company Teva will close a manufacturing plant in Dublin from the third quarter of 2022. The closure is scheduled to be completed by January of 2023 and will result in the loss of 110 jobs.

Production at the plant, which manufactures nappy rash cream Sudocrem is to move to Bulgaria.

The senior director of corporate affairs for Teva UK and Ireland said that the Baldoyle plant does not have the capacity to grow any further and as part of global consolidation plans it has decided to move production to an existing plant in Bulgaria.

For previous restructuring event related to Teva in Ireland, see Teva-IE-2009. 

Sources

Citation

Eurofound (2021), Teva, Offshoring/Delocalisation in Ireland, factsheet number 105007, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/105007.